Industry news
AstraZeneca enters into agreement to acquire the respiratory business of Takeda including Daliresp/Daxas (roflumilast)
AstraZeneca has announced that it has entered into a definitive agreement to acquire the core respiratory business of Takeda. The deal will include the expansion of rights to roflumilast (marketed as Daliresp in the US and Daxas in other countries), the only approved oral PDE4 inhibitor for the treatment of chronic obstructive pulmonary disease (COPD).
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins